Berman Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Berman Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$71K	Buy	936 +348	+59%	+$27.5K	0.01%	546
2021 Q2	$48K	Buy	588 +183	+45%	+$14.5K	0.01%	595
2021 Q1	$30K	Sell	405 -176	-30%	-$14.4K	0.01%	655
2020 Q4	$50K	Buy	581 +498	+600%	+$39.5K	0.01%	406
2020 Q3	$6K	Sell	83 -95	-53%	-$9.61K	﹤0.01%	955
2020 Q2	$21K	Buy	178 +85	+91%	+$8.45K	0.01%	528
2020 Q1	$7K	Buy	+93	New	+$8.01K	﹤0.01%	759
2019 Q4	–	Sell	-98	Closed	-$6K	–	1463
2019 Q3	$6K	Sell	98 -144	-60%	-$11.1K	﹤0.01%	878
2019 Q2	$20K	Sell	242 -175	-42%	-$15K	0.01%	511
2019 Q1	$36K	Buy	417 +151	+57%	+$14K	0.01%	327
2018 Q4	$22K	Buy	+266	New	+$25.3K	0.01%	367

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Berman Capital Advisors's BMRN Position: Q3 2021 in Review

Berman Capital Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 59% in Q3 2021, buying an estimated $27.5K and bringing the position to 936 shares worth $71K. The position accounts for 0.01% of the portfolio, ranked #546.

Berman Capital Advisors first reported a position in BMRN in Q4 2018 and has held it in 11 quarters since. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Berman Capital Advisors held 936 shares of BioMarin Pharmaceuticals worth $71K as of Q3 2021.
Berman Capital Advisors bought 348 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $27.5K.
BioMarin Pharmaceuticals made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #546 holding.
Berman Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 11 quarters since.
512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.